GLP-1 Market
LLY $1152.70 ▲ +0.0% NVO $43.24 ▲ +0.1% PFE $27.61 ▼ -0.1% VKTX $28.99 ▼ -1.3% KLRA $12.83 ▼ -0.7% GPCR $35.00 ▼ -0.3% RHHBY $54.04 ▼ -1.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Arhalofenate

Company
Gilead Sciences
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 19, 2026

Trial details
  • Completed NCT NCT00353587

    Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

    Not yet reported, Not yet reported Gilead Sciences 396 participants Est. completion 2007-11 67 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Terminated NCT NCT00814372

    Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

    Not yet reported Gilead Sciences 242 participants Est. completion 2010-02 26 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01336686

    Safety and Efficacy Study of MBX-102 in Treatment of Hyperuricemia in Patients With Gout

    Not yet reported Gilead Sciences 67 participants Est. completion 2011-11 12 sites Stand-alone
    Other conditions: Hyperuricemia, Gout
    View official trial listing →
  • Completed NCT NCT01399008

    Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

    Not yet reported Gilead Sciences 100 participants Est. completion 2012-02 24 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT01416402

    Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

    Not yet reported Gilead Sciences 27 participants Est. completion 2011-10 1 site
    Other conditions: Hyperuricemia, Gout
    View official trial listing →
  • Completed NCT NCT02063997

    Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients

    Not yet reported Gilead Sciences 248 participants Est. completion 2015-01 56 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Completed NCT NCT02252835

    Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout

    Not yet reported Gilead Sciences 32 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Gout, Hyperuricemia
    View official trial listing →
  • Completed NCT NCT04467684

    Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406

    Not yet reported Gilead Sciences 90 participants Est. completion 2021-06-06 1 site
    Other conditions: Healthy Volunteers
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Arhalofenate, MBX-102

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.